image
Industrials - Manufacturing - Metal Fabrication - NYSE - US
$ 56.17
-0.0356 %
$ 8.01 B
Market Cap
21.6
P/E
1. INTRINSIC VALUE

ATI Inc. manufactures and sells specialty materials and components worldwide. The company operates in two segments: High Performance Materials & Components (HPMC) and Advanced Alloys & Solutions (AA&S). The HPMC segment produces various materials, including titanium and titanium-based alloys, nickel- and cobalt-based alloys and superalloys, advanced powder alloys and other specialty materials, in long product forms, such as ingot, billet, bar, rod, wire, shapes and rectangles, and seamless tubes, as well as precision forgings, components, and machined parts. The segment serves aerospace and defense, medical, and energy markets. The AA&S segment produces zirconium and related alloys, including hafnium and niobium, nickel-based alloys, titanium and titanium-based alloys, and specialty alloys in a variety of forms, such as plate, sheet, and precision rolled strip products.[ Read More ]

The intrinsic value of one ATI stock under the base case scenario is HIDDEN Compared to the current market price of 56.2 USD, ATI Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ATI

image
FINANCIALS
4.17 B REVENUE
8.80%
466 M OPERATING INCOME
62.34%
411 M NET INCOME
180.41%
85.9 M OPERATING CASH FLOW
-61.81%
-193 M INVESTING CASH FLOW
-52.49%
267 M FINANCING CASH FLOW
232.34%
1.05 B REVENUE
-4.03%
142 M OPERATING INCOME
2.67%
86.6 M NET INCOME
5.74%
24 M OPERATING CASH FLOW
-76.26%
-61.1 M INVESTING CASH FLOW
-14.63%
27.7 M FINANCING CASH FLOW
495.71%
Balance Sheet Decomposition ATI Inc.
image
Current Assets 2.74 B
Cash & Short-Term Investments 744 M
Receivables 684 M
Other Current Assets 1.31 B
Non-Current Assets 2.25 B
Long-Term Investments 0
PP&E 1.67 B
Other Non-Current Assets 582 M
Current Liabilities 977 M
Accounts Payable 525 M
Short-Term Debt 31.9 M
Other Current Liabilities 420 M
Non-Current Liabilities 2.53 B
Long-Term Debt 2.22 B
Other Non-Current Liabilities 309 M
EFFICIENCY
Earnings Waterfall ATI Inc.
image
Revenue 4.17 B
Cost Of Revenue 3.37 B
Gross Profit 803 M
Operating Expenses 328 M
Operating Income 466 M
Other Expenses 55.6 M
Net Income 411 M
RATIOS
19.23% GROSS MARGIN
19.23%
11.17% OPERATING MARGIN
11.17%
9.84% NET MARGIN
9.84%
29.92% ROE
29.92%
8.24% ROA
8.24%
18.83% ROIC
18.83%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ATI Inc.
image
Net Income 411 M
Depreciation & Amortization 146 M
Capital Expenditures -201 M
Stock-Based Compensation 29.1 M
Change in Working Capital -378 M
Others -234 M
Free Cash Flow -115 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ATI Inc.
image
Wall Street analysts predict an average 1-year price target for ATI of $73 , with forecasts ranging from a low of $66 to a high of $84 .
ATI Lowest Price Target Wall Street Target
66 USD 17.50%
ATI Average Price Target Wall Street Target
73 USD 29.96%
ATI Highest Price Target Wall Street Target
84 USD 49.55%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.08 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership ATI Inc.
image
Sold
0-3 MONTHS
3.1 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
2.49 M USD 2
9-12 MONTHS
871 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Oct 15, 2024
Sell 1.56 M USD
WETHERBEE ROBERT S
Executive Chairman
- 25000
62.23 USD
2 months ago
Sep 16, 2024
Sell 1.54 M USD
WETHERBEE ROBERT S
Executive Chairman
- 25000
61.61 USD
8 months ago
Feb 29, 2024
Sell 2.23 M USD
Davis Elliot S
Chief Legal & Compl. Officer
- 45351
49.12 USD
9 months ago
Feb 12, 2024
Sell 268 K USD
Harris Timothy J
Senior VP and CDIO
- 6325
42.44 USD
9 months ago
Feb 13, 2024
Sell 265 K USD
Harris Timothy J
Senior VP and CDIO
- 6325
41.88 USD
10 months ago
Jan 03, 2024
Sell 526 K USD
Davis Elliot S
Chief Legal & Compl. Officer
- 12123
43.37 USD
10 months ago
Jan 04, 2024
Sell 77 K USD
Davis Elliot S
Chief Legal & Compl. Officer
- 1789
43.06 USD
1 year ago
Sep 08, 2023
Sell 120 K USD
DIGGS JAMES C
Director
- 2674
44.9 USD
1 year ago
Aug 10, 2023
Sell 560 K USD
Harris Timothy J
Senior VP and CDIO
- 12858
43.57 USD
1 year ago
Jul 10, 2023
Sell 317 K USD
Davis Elliot S
Chief Legal & Compl. Officer
- 7039
45 USD
1 year ago
Jun 29, 2023
Sell 299 K USD
Davis Elliot S
Chief Legal & Compl. Officer
- 7039
42.5 USD
1 year ago
Jun 12, 2023
Sell 282 K USD
Davis Elliot S
Chief Legal & Compl. Officer
- 7039
40 USD
1 year ago
Feb 08, 2023
Sell 376 K USD
Davis Elliot S
Chief Legal & Compl. Officer
- 9627
39.0747 USD
1 year ago
Dec 06, 2022
Sell 877 K USD
Davis Elliot S
Chief Legal & Compl. Officer
- 28571.832
30.6798 USD
2 years ago
Nov 01, 2022
Sell 453 K USD
WETHERBEE ROBERT S
Board Chair, President and CEO
- 15000
30.23 USD
2 years ago
Oct 03, 2022
Sell 407 K USD
WETHERBEE ROBERT S
Board Chair, President and CEO
- 15000
27.13 USD
2 years ago
Sep 12, 2022
Sell 31.3 K USD
Schwartz Karl D
VP, Controller & CAO
- 1000
31.32 USD
2 years ago
Sep 01, 2022
Sell 436 K USD
WETHERBEE ROBERT S
Board Chair, President and CEO
- 15000
29.09 USD
2 years ago
Aug 11, 2022
Sell 31.2 K USD
Schwartz Karl D
VP, Controller & CAO
- 1000
31.22 USD
2 years ago
Jul 28, 2022
Sell 50 K USD
Schwartz Karl D
VP, Controller & CAO
- 2000
25 USD
2 years ago
Jul 19, 2022
Sell 300 K USD
DIGGS JAMES C
director:
- 12500
24 USD
2 years ago
May 09, 2022
Sell 26 K USD
Schwartz Karl D
VP, Controller & CAO
- 1000
25.96 USD
2 years ago
Apr 14, 2022
Sell 300 K USD
Kramer Kevin B
Sr. VP, CCMO
- 10000
30 USD
2 years ago
Mar 07, 2022
Sell 270 K USD
Kramer Kevin B
Sr. VP, CCMO
- 10000
27 USD
3 years ago
Jun 01, 2021
Sell 250 K USD
Kramer Kevin B
Sr. VP, CCMO
- 10000
25 USD
3 years ago
Mar 15, 2021
Sell 218 K USD
Kramer Kevin B
Sr. VP, CCMO
- 9900
22 USD
3 years ago
Mar 15, 2021
Sell 2.2 K USD
Kramer Kevin B
Sr. VP, CCMO
- 100
22.01 USD
3 years ago
Mar 11, 2021
Sell 342 K USD
Davis Elliot S
Sr VP, GC, CCO and Secretary
- 15200
22.5 USD
3 years ago
Mar 05, 2021
Sell 167 K USD
Davis Elliot S
Sr VP, GC, CCO and Secretary
- 8233
20.34 USD
3 years ago
Dec 10, 2020
Bought 210 K USD
NEWMAN DONALD P
SVP and CFO
+ 12500
16.8292 USD
4 years ago
Mar 16, 2020
Bought 17.8 K USD
Kah Marianne
Director
+ 2000
8.91 USD
4 years ago
Mar 16, 2020
Bought 21.8 K USD
WETHERBEE ROBERT S
President and CEO
+ 2500
8.7035 USD
5 years ago
Aug 14, 2019
Bought 36.3 K USD
Powers Elizabeth C
Senior VP, CHRO
+ 2000
18.17 USD
5 years ago
Aug 14, 2019
Bought 44.2 K USD
Kramer Kevin B
Sr. VP, CCMO
+ 2500
17.6832 USD
5 years ago
Aug 14, 2019
Bought 51.6 K USD
Harris Timothy J
Senior VP and CDIO
+ 2900
17.8 USD
5 years ago
Aug 14, 2019
Bought 35.1 K USD
Davis Elliot S
Sr VP, GC, CCO and Secretary
+ 2000
17.53 USD
5 years ago
Aug 13, 2019
Bought 36.4 K USD
BALL M LEROY
Director
+ 2000
18.18 USD
5 years ago
Aug 13, 2019
Bought 91.8 K USD
WETHERBEE ROBERT S
President and CEO
+ 5000
18.36 USD
5 years ago
Jun 17, 2019
Sell 94.6 K USD
DIGGS JAMES C
Director
- 4000
23.65 USD
5 years ago
Feb 28, 2019
Sell 314 K USD
HARSHMAN RICHARD J
Executive Chairman
- 10780
29.13 USD
5 years ago
Feb 26, 2019
Sell 588 K USD
HARSHMAN RICHARD J
Executive Chairman
- 20208
29.12 USD
5 years ago
Feb 21, 2019
Sell 207 K USD
HARSHMAN RICHARD J
Executive Chairman
- 7140
28.99 USD
5 years ago
Jan 24, 2019
Sell 192 K USD
JEREMIAH BARABARA S
Director
- 7500
25.608 USD
6 years ago
Oct 15, 2018
Sell 27.1 K USD
Schwartz Karl D
VP, Controller & CAO
- 1000
27.1 USD
6 years ago
Sep 17, 2018
Sell 26.8 K USD
Schwartz Karl D
VP, Controller & CAO
- 1000
26.79 USD
6 years ago
Aug 15, 2018
Sell 25.9 K USD
Schwartz Karl D
VP, Controller & CAO
- 1000
25.9 USD
6 years ago
Jul 26, 2018
Sell 112 K USD
DIGGS JAMES C
Director
- 3844
29.15 USD
6 years ago
Jul 16, 2018
Sell 26.6 K USD
Schwartz Karl D
VP, Controller & CAO
- 1000
26.65 USD
6 years ago
Jun 15, 2018
Sell 27.3 K USD
Schwartz Karl D
VP, Controller & CAO
- 1000
27.34 USD
6 years ago
Apr 26, 2018
Sell 27.1 K USD
Schwartz Karl D
VP, Controller & CAO
- 1000
27.12 USD
6 years ago
Apr 26, 2018
Sell 820 K USD
Sims John D
EVP, HPMC Segment
- 30000
27.3448 USD
8 years ago
Dec 16, 2015
Bought 52.2 K USD
Powers Elizabeth C
Senior VP, CHRO
+ 5000
10.43 USD
8 years ago
Dec 15, 2015
Bought 20.2 K USD
Powers Elizabeth C
Senior VP, CHRO
+ 1872
10.78 USD
8 years ago
Dec 15, 2015
Bought 30 K USD
Powers Elizabeth C
Senior VP, CHRO
+ 2788
10.77 USD
9 years ago
Oct 28, 2015
Bought 28.7 K USD
Davis Elliot S
Sr VP, GC, CCO and Secretary
+ 2000
14.36 USD
9 years ago
Oct 28, 2015
Bought 20.3 K USD
HARSHMAN RICHARD J
Chairman, President and CEO
+ 1400
14.53 USD
9 years ago
Oct 28, 2015
Bought 8.72 K USD
HARSHMAN RICHARD J
Chairman, President and CEO
+ 600
14.54 USD
9 years ago
Oct 28, 2015
Bought 4.86 K USD
HARSHMAN RICHARD J
Chairman, President and CEO
+ 334
14.55 USD
9 years ago
Oct 28, 2015
Bought 24.8 K USD
HARSHMAN RICHARD J
Chairman, President and CEO
+ 1700
14.57 USD
9 years ago
Oct 28, 2015
Bought 196 K USD
HARSHMAN RICHARD J
Chairman, President and CEO
+ 13466
14.58 USD
9 years ago
Oct 26, 2015
Bought 5.74 K USD
Kramer Kevin B
Sr. VP, CCMO
+ 400
14.35 USD
9 years ago
Oct 26, 2015
Bought 22.9 K USD
Kramer Kevin B
Sr. VP, CCMO
+ 1600
14.32 USD
9 years ago
Oct 22, 2015
Bought 27.4 K USD
Pipski John R
Director
+ 2000
13.69 USD
9 years ago
Oct 22, 2015
Bought 41.2 K USD
Pipski John R
Director
+ 3000
13.74 USD
9 years ago
Oct 22, 2015
Bought 27.4 K USD
Pipski John R
Director
+ 2000
13.69 USD
9 years ago
Jul 27, 2015
Bought 10.7 K USD
ROHR JAMES E
Director
+ 500
21.31 USD
9 years ago
Jul 27, 2015
Bought 6.4 K USD
ROHR JAMES E
Director
+ 300
21.33 USD
7. News
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal models after one year Alignment with U.S. Food and Drug Administration on development requirements for ATI-1801 NDA Submission HALIFAX, Nova Scotia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the second quarter of its fiscal year 2025, which ended on September 30, 2024. All figures are stated in Canadian dollars unless otherwise stated. globenewswire.com - 3 days ago
For 5th Consecutive Year, ATI Physical Therapy Achieves 'Exceptional' Rating In Patient Quality from the Center For Medicare and Medicaid Services (MIPS) The Achievement Continues the Company's Streak in Earning the Rating Annually Since the Program Debuted in 2019 BOLINGBROOK, Ill. , Nov. 13, 2024 /PRNewswire/ -- ATI Physical Therapy  ("ATI" or the "Company") today has again earned the "Exceptional" rating from the Center for Medicare and Medicaid Services' (CMS) Merit-Based Incentive Payment System (MIPS) for quality patient care. prnewswire.com - 3 days ago
ATI announces sale of precision rolled strip operations to Ulbrich Sharpens focus on strategic aerospace and defense markets, streamlines operations DALLAS , Nov. 6, 2024 /PRNewswire/ -- ATI Inc. (NYSE: ATI) announced it completed the sale of its precision rolled strip operations in New Bedford, Massachusetts and Remscheid, Germany to Ulbrich Stainless Steels and Special Metals, Inc. (Ulbrich). "With this divestiture, ATI sharpens its focus on providing our aerospace and defense customers with the titanium, nickel, and alloyed products that are rolled, melted and/or finished throughout Specialty Rolled Products facilities," said Kimberly A. prnewswire.com - 1 week ago
ATI Physical Therapy Reports Third Quarter 2024 Results BOLINGBROOK, Ill. , Nov. 4, 2024 /PRNewswire/ -- ATI Physical Therapy, Inc. (NYSE: ATIP) ("ATI" or the "Company"), a nationally recognized outpatient physical therapy provider in the United States, today reported financial results for the third quarter ended September 30, 2024. prnewswire.com - 1 week ago
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for the November 6, 2024 shareholders meeting HALIFAX, Nova Scotia, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that the U.S. Food and Drug Administration (“FDA”) has provided positive feedback regarding the development strategy for ATI-1801, and agreed on the necessary registration package to support a New Drug Application (“NDA”). ATI-1801, a novel topical formulation of paromomycin (15% w/w), is under advanced clinical development for treating cutaneous leishmaniasis, a disfiguring skin infection affecting hundreds of thousands globally. globenewswire.com - 2 weeks ago
ATI's Earnings Miss Estimates in Q3, Revenues Increase Y/Y ATI saw higher year-over-year sales in aerospace and defense in the third quarter. zacks.com - 2 weeks ago
ATI Inc (ATI) Q3 2024 Earnings Call Transcript ATI Inc (NYSE:ATI ) Q3 2024 Results Conference Call October 29, 2024 8:30 AM ET Company Participants David Weston - Vice President of Investor Relations Kim Fields - President, CEO & Director Don Newman - Executive VP of Finance & CFO Conference Call Participants Richard Safran - Seaport Research Partners Andre Madrid - BTIG David Strauss - Barclays Phil Gibbs - KeyBanc Capital Markets Timna Tanners - Wolfe Research Seth Seifman - JPMorgan Scott Deuschle - Deutsche Bank Operator Hello, everyone, and welcome to ATI's Third Quarter 2024 Earnings Call. My name is Lydia, and I will be your operator today. seekingalpha.com - 2 weeks ago
Allegheny Technologies (ATI) Q3 Earnings and Revenues Lag Estimates Allegheny Technologies (ATI) came out with quarterly earnings of $0.60 per share, missing the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.55 per share a year ago. zacks.com - 2 weeks ago
ATI Announces Third Quarter 2024 Results Ninth consecutive quarter with sales in excess of $1 billion Q3 2024 sales of $1.05 billion Q3 2024 net income attributable to ATI of $82.7 million, or $0.57 per share Aerospace & defense represent 62% of Q3 2024 sales Full year 2024 guidance updated Non-GAAP Information* Q3 adjusted net income attributable to ATI of $85.9 million, or $0.60 per share Q3 2024 ATI adjusted EBITDA of $185.7 million, or 17.7% of sales, up 100 basis points sequentially DALLAS , Oct. 29, 2024 /PRNewswire/ -- ATI Inc. (NYSE: ATI) reported third quarter 2024 results, with sales of $1.05 billion and net income attributable to ATI of $82.7 million, or $0.57 per share.     Sequential Y-O-Y ($ in millions except per share amounts) Q3 2024 Q2 2024 Change Q3 2023 Change Sales $1,051.2 $1,095.3 (4) % $1,025.6 2 % Net income attributable to ATI $82.7 $81.9 1 % $90.2 (8) % Earnings per share $0.57 $0.58 (2) % $0.62 (8) % Non-GAAP information* Adjusted net income attributable to ATI* $85.9 $86.0 — % $94.2 (9) % Adjusted earnings per share* $0.60 $0.60 — % $0.64 (6) % ATI adjusted EBITDA* $185.7 $182.6 2 % $162.6 14 % * Detailed reconciliations of the reported information under accounting principles generally accepted in the United States (U.S. GAAP) to adjusted non-GAAP figures are included in accompanying financial tables. prnewswire.com - 2 weeks ago
Allegheny Technologies (ATI) Reports Next Week: Wall Street Expects Earnings Growth Allegheny Technologies (ATI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 weeks ago
ATI Physical Therapy to Announce Third Quarter 2024 Financial Results BOLINGBROOK, Ill. , Oct. 21, 2024 /PRNewswire/ -- ATI Physical Therapy, Inc. – ("ATI" or the "Company") (NYSE: ATIP), a nationally recognized outpatient physical therapy provider in the United States, today announced that it will release third quarter 2024 financial results on Monday, November 4, 2024, after the market closes. prnewswire.com - 3 weeks ago
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024 ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy Presentation scheduled for 3:15 pm ET on October 17, 2024 HALIFAX, Nova Scotia, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that Gary Nabors, Ph.D., Chief Development Officer, and key members of Appili's scientific team, will participate at IDWeek 2024™, and present an update on the Appili biodefense program ATI-1701. globenewswire.com - 1 month ago
8. Profile Summary

ATI Inc. ATI

image
COUNTRY US
INDUSTRY Manufacturing - Metal Fabrication
MARKET CAP $ 8.01 B
Dividend Yield 0.00%
Description ATI Inc. manufactures and sells specialty materials and components worldwide. The company operates in two segments: High Performance Materials & Components (HPMC) and Advanced Alloys & Solutions (AA&S). The HPMC segment produces various materials, including titanium and titanium-based alloys, nickel- and cobalt-based alloys and superalloys, advanced powder alloys and other specialty materials, in long product forms, such as ingot, billet, bar, rod, wire, shapes and rectangles, and seamless tubes, as well as precision forgings, components, and machined parts. The segment serves aerospace and defense, medical, and energy markets. The AA&S segment produces zirconium and related alloys, including hafnium and niobium, nickel-based alloys, titanium and titanium-based alloys, and specialty alloys in a variety of forms, such as plate, sheet, and precision rolled strip products. It also provides hot-rolling conversion services, including carbon steel products, and titanium products. This segment offers its solutions to the energy, aerospace and defense, automotive, and electronics markets. The company was formerly known as Allegheny Technologies Incorporated. ATI Inc. was founded in 1960 and is headquartered in Dallas, Texas.
Contact ATI Corporate, Dallas, TX, 75201 https://www.atimaterials.com
IPO Date Nov. 29, 1999
Employees 7300
Officers Ms. Netta Washington Executive Vice President Mr. John S. Minich President of Forged Products Mr. David Weston Vice President of Investor Relations Ms. Vaishali S. Bhatia Senior Vice President, General Counsel & Chief Compliance Officer Ms. Tina Killough Busch Senior Vice President & Chief Human Resources Officer Ms. Kimberly A. Fields President, Chief Executive Officer & Director Mr. Timothy J. Harris Senior Vice President and Chief Digital & Information Officer Dr. Jimmy Williams Jr. Senior Vice President & Chief Technology Officer Mr. Robert S. Wetherbee Executive Chairman Mr. Michael Benjamin Miller Vice President, Corporate Controller & Chief Accounting Officer